Lupus & antiphospholipid syndrome
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis
Authors' conclusion
Rituximab followed by belimumab or telitacicept may be effective in inducing remission in refractory lupus nephritis, with tolerable adverse effects.
Study context
- Population
- Patients with refractory LN
- Participants
- 25 patients
- Exposure
- RTX followed by belimumab or telitacicept
- Rituximab plus belimumabn = 18
- Rituximab plus telitaciceptn = 7
- Outcome
- Renal remission rate
- Follow-up
- Last
Methodological detailssingle-center, open-label, RTX dose 712 ± 416mg in average
- Single-center
- Open-label
- RTX dose 712 ± 416mg in average
Main finding
As reported in the abstract
Renal remission · last follow-up (median 19 (13, 29) months)
| Group | Value | Complete renal response (CRR) | OR |
|---|---|---|---|
| Rituximab plus belimumab | 66.7% | 12 (66.7%) | 13 (72.2%) |
| Rituximab plus telitacicept | all patients |
Value
Rituximab plus belimumab66.7%
Rituximab plus telitacicept— not stated in the abstract
Complete renal response (CRR)
Rituximab plus belimumab12 (66.7%)
Rituximab plus telitaciceptall patients
OR
Rituximab plus belimumab13 (72.2%)
Rituximab plus telitacicept— not stated in the abstract
- Objective remission (OR), overall
- 20 of 25 (80%)
- CRR, overall
- 19 (76%)
Observational data: associations, not effects.
Further findings
Mean SLEDAI-2K score
- Decreased from 15 ± 6 to 6 ± 6
- average reduction of 60%
Prednisone ≤ 5 mg/d or discontinued · last follow-up
- Patients
- 18/25 (72%)
Safety
Adverse effects
- Deaths
- 0
- Mainly immunoglobulin deficiency, respiratory tract infection, urinary tract infections, and rash
Original publication
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis. Rheumatology (Oxford). Published 9 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →